Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|November 24, 2015
Bacterial Endotoxin Testing by LAL
GMP/GLP compliant testing laboratory, Wickham Laboratories Ltd, offers a dedicated in vitro bacterial endotoxin service for clients requiring biocompatibility testing.
Advertisement
Wickham Laboratories offers biocompatibility assessment via the Limulus Amebocyte Lysate (LAL) method to those of our clients requiring bacterial endotoxin screening. With over 20 years of experience in bacterial endotoxin testing, we are uniquely equipped to deal with your challenging and complicated samples, including cytotoxics.
LAL is an established in vitro test for the screening of parenteral medicines, irrigation fluids, dialysis solutions, purified water and medical devices. We offer all three standard LAL methods: gel clot, kinetic chromogenic and kinetic turbidimetric, working closely with our clients to determine which method is best for their particular requirements.
As a GMP/GLP compliant laboratory with over 50 years of experience, we are an established name in the fields of pharmaceutical and medical device contract testing, research and consultancy. We are routinely inspected by the MHRA, FDA and Home Office and maintain an audit ready facility at all times.
Conducting business with clients worldwide, the combined expertise of our laboratory technicians and managers enables us to be fully conversant with global regulatory expectations. For more information about Wickham Laboratories Limited and our services, please contact us at +44 (0)1329 226600 or
Contact Details:
Wickham Laboratories Ltd
Website:
E-mail: mail@wickhamlabs.co.uk
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
What the Olanzapine Depot Approval Means for CMC Teams
3
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
4
Complying with International Pharmacopoeias
5